Could a Diabetes Drug Revolutionize Alcohol Addiction Treatment?

A drug originally used for diabetes and weight loss, tirzepatide (Mounjaro), could soon play a major role in treating alcohol addiction. Tirzepatide has shown striking results in animal studies, cutting alcohol intake by more than half. Researchers now believe it may trigger lasting changes in the brain that curb addictive behaviour.

Scientists at the University of Gothenburg discovered that tirzepatide drastically reduces alcohol consumption in lab animals. The drug lowered intake by over 50% and also reduced the likelihood of relapse. Unlike existing treatments, it works by quietening the brain's dopamine response to alcohol, effectively dulling the reward system that drives addiction.

Tirzepatide stands out from similar medications like semaglutide because it targets two key receptors—GIP and GLP-1. This dual action may give it a stronger effect on addictive behaviour. Early findings even suggest it could cause epigenetic changes, meaning its benefits might persist long after treatment ends.

Despite these promising results, no clinical trials for tirzepatide in alcohol dependence have yet been submitted to regulators like the EMA or FDA. The drug is currently approved only for type 2 diabetes and obesity. However, its existing approval could speed up future testing, as safety data is already well-established.

Tirzepatide's potential to treat alcohol addiction marks a significant shift in addiction medicine. If human trials confirm the animal study results, it could offer a new, more effective option for those struggling with dependence. For now, further research remains necessary before the drug can be repurposed for this use.